Multimeric Biotherapeutics, Inc.

La Jolla, CA 92037

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.27MM
First Award Date 08/06/13
Most Recent Award Date 09/30/16

Key Personnel

Last Name Name Awards Contact
Kornbluth Richard Syd Kornbluth 5

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/30/16 - 08/31/17

Ebola virus (EBOV) is a dreaded virus that periodically emerges from its animal reservoir to cause serious and deadly epidemics. A recently developed replicating viral vaccine (rVSV-ZEBOV) was successfully used as a post-exposure vaccine for persons at high risk following exposure. However, this antibody-inducing vaccine has caused fever and art...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-077
Budget: 09/23/15 - 08/31/16

DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) infection, while preventable by routine vaccination, has already led to chronic HBV infection (CHB) in about 240 million people worldwide. Although antiviral drugs are available, these must be taken daily for life and are unaffordable for most of world's CHB population. Consequently, ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/14 - 07/31/15

DESCRIPTION (provided by applicant): CD40 ligand (CD40L or CD154) is widely recognized as one of the most important endogenous activators of the immune system. In particular, CD40L stimulates dendritic cells (DCs) to initiate strong CD8+ T cell responses. However, despite several attempts, no form of CD40L has been licensed for clinical use. To...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 06/01/14 - 05/31/15

Advanced ovarian cancer is a difficult condition for which new treatments are urgently needed. CD40 ligand (CD40L) is a candidate for the treatment of this disease because most ovarian cancer cells express the CD40 receptor. CD40L stimulation of this receptor kills the cancer cells, but has no cytotoxic effects on normal cells. In vivo, CD40L mo...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/06/13 - 07/31/14

DESCRIPTION (provided by applicant): CD40 ligand (CD40L or CD154) is widely recognized as one of the most important endogenous activators of the immune system. In particular, CD40L stimulates dendritic cells (DCs) to initiate strong CD8+ T cell responses. However, despite several attempts, no form of CD40L has been licensed for clinical use. To...